Application of red blood cell apheresis in a case of juvenile polycythemia vera
10.13303/j.cjbt.issn.1004-549x.2026.05.014
- VernacularTitle:红细胞单采术治疗青少年真性红细胞增多症1例
- Author:
Jie YANG
1
;
Chengxin ZHANG
1
;
Xinxin HAO
1
;
Simeng WU
1
;
Qiushi WANG
1
Author Information
1. Shengjing Hospital of China Medical University, Shenyang 110004, China
- Publication Type:Journal Article
- Keywords:
erythrocytapheresis;
polycythemia vera;
case report
- From:
Chinese Journal of Blood Transfusion
2026;39(5):673-676
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To retrospectively investigate the clinical efficacy, safety, and management experience of a patient diagnosed with polycythemia vera (PV) at the age of 3 who underwent regular erythrocytapheresis for 7 years starting at the age of 10. Methods: Treatment was initiated when the patient's hematocrit was≥50%. The goal was to reduce the hematocrit to below 40%; the removal volume was calculated as 10%-15% of the total red blood cell mass, and an equal volume of normal saline was supplemented during the procedure. Pre-treatment precautions included avoiding fasting and high-fat diets. Post-treatment measures included lying flat for 30 minutes, reducing strenuous exercise for 2–3 days, and rechecking complete blood count 2–5 days after the procedure. During the procedure, adverse reactions such as palpitations, dyspnea, hypotension, and convulsions were monitored. Follow-up was conducted after 3 days to assess any delayed adverse effects. Results: As of August 2025, the patient had undergone a total of 16 erythrocytapheresis sessions. The average volume ranged from 212 to 500 mL. The frequency was 1 to 4 times annually. Post-procedure, hemoglobin (Hb) and hematocrit (Hct) were effectively controlled. Conclusion: Continuous erythrocytapheresis can effectively control Hb and Hct levels in PV patients, preventing adverse effects from the primary disease. Erythrocytapheresis demonstrates efficacy with minimal adverse reactions and can be used as a routine therapeutic technique for PV patients.
